Biogen Inc. is seeing a positive uptick in its stock price as it builds momentum ahead of its upcoming earnings report.
Biogen Inc. (NASDAQ:BIIB) is rising today, with shares up by 1.40% to close at CA$226.01. The company is benefiting from a strong earnings surprise history and promising developments in its clinical trials.
Advertisement
Biogen Inc
BIIB.US
BIIB.US
Biogen Inc
WealthAwesomeMarket cap
$33.35B
P/E
40.1x
52W high
$230.49
52W low
$138.00
1W change
+2.65%
Beta
0.09
Analyst Price Targets
Based on 35 analysts covering BIIB · as of Oct 12, 2026
Wall Street analysts forecast BIIB stock price to rise 6.0% over the next 12 months.
Consensus
Buy4.11 / 5.00
Avg. Target
C$239.18
+6.0% Upside
Previously C$238.18 on Oct 5, 2026
Current Price
C$225.71
Last close
Analyst Breakdown (35 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BIIB's historical volatility
30-Day Vol
25.4%
Annualized
90-Day Vol
35.2%
Annualized
Trend (90d)
+32.5%
Annualized drift
90d Mean
C$253.46
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$234.60 | C$214.89 – C$256.12 |
| 60 trading days | C$243.85 | C$215.39 – C$276.07 |
| 90 trading days | C$253.46 | C$217.72 – C$295.07 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about Biogen's potential to continue beating earnings estimates, especially with its upcoming quarterly report and positive clinical trial results.
1.40% Increase in Stock Price
Biogen's stock is currently trading at CA$226.01, reflecting a 1.40% increase driven by strong earnings expectations and recent positive clinical data.
Bull case
Biogen has a solid track record of exceeding earnings estimates, averaging a surprise of 19.72% over the last two quarters. The company’s positive Earnings ESP indicates it may keep this trend going, which could lead to further stock growth.
Bear case
On the flip side, Biogen's high P/E ratio of 39.59 suggests the stock might be overvalued. If the company misses earnings expectations, it could trigger a significant pullback in the stock price.
Advertisement
Strong Earnings History
Biogen has shown a remarkable ability to exceed earnings estimates in its recent reports. For example, in the last quarter, the company reported earnings of $3.6 per share, surpassing expectations of $3.04, resulting in an 18.42% surprise. This trend has boosted investor confidence as the company approaches its next earnings report scheduled for October 28, 2026.
Promising Clinical Developments
Recent data from Biogen's Phase 2 clinical trial for litifilimab, a treatment for cutaneous lupus erythematosus, has shown significant improvements in patient outcomes. With 27.2% of participants achieving clear or almost clear skin after one year, the results strengthen the drug's potential and align with Biogen's strategy to expand its portfolio in autoimmune diseases. This positive news is likely contributing to the stock's upward movement.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
